WO2012000151A1 - 基于solexa测序法的检测人类乳头瘤病毒的方法 - Google Patents
基于solexa测序法的检测人类乳头瘤病毒的方法 Download PDFInfo
- Publication number
- WO2012000151A1 WO2012000151A1 PCT/CN2010/001833 CN2010001833W WO2012000151A1 WO 2012000151 A1 WO2012000151 A1 WO 2012000151A1 CN 2010001833 W CN2010001833 W CN 2010001833W WO 2012000151 A1 WO2012000151 A1 WO 2012000151A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequencing
- sequence
- pcr
- sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/708—Specific hybridization probes for papilloma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
Definitions
- the invention relates to a detection method of human papillomavirus (Human Papi viv Virus, HPV), in particular to an HPV detection method based on So lexa sequencing method. Background technique
- Cervical cancer is the second killer of female cancer in the world, second only to breast cancer. There are about 500,000 new cases and 250,000 deaths worldwide each year, of which 2/3 are in developing countries. China is a high-risk area for cervical cancer, accounting for 10% of the total number of cervical cancers worldwide.
- HPV human papillomavirus
- More than 100 HPVs have been shown to infect the skin (skin type) or the mucous membranes of the respiratory and anal genital tract (mucosal types), and more than 40 HPVs can infect the cervix.
- HPV is classified into low-risk types (eg, HPV6, 11, 42, 43 and 44) and high-risk types (eg ⁇ 6, 18, 31, 33 and 45) based on induced benign, premalignant or malignant lesions. . Therefore, early detection and correct typing of HPV infection is critical for the prevention and treatment of cervical cancer.
- HPV detection methods mainly include the following: 1 cytological examination, which uses cervical smear cytology or liquid-based thin-layer cytology to diagnose by the change of cell appearance. For HPV infection, hollowed out cells, poor keratosis, and underlying cells of the sputum are visible under the microscope. The limitation is that the diagnosis and the specificity of HPV infection are low. 2 Immunohistochemical method, which further clarifies HPV infection by detecting the capsid antigen of HPV, and the positive reaction obtained by the method is clearly defined and reliable. However, capsid antigens are only produced after HPV-DM replication is matured, so subjects diagnosed negative cannot be determined to be uninfected by HPV, and the method is less sensitive.
- FQ-PCR real-time fluorescence Quantitative PCR
- HC-II system which is currently the only FDA-approved HP V DNA test method for clinical use, and it has obtained European CE and Chinese SDA certification.
- the method uses a dedicated specimen collection saver; a patented full-length 8000 bp RM probe and a patented specific first antibody.
- the principle is that the nucleic acid probe is hybridized to the HPV DN A of the test subject, and then detected by chemical fluorescence or enzymatic reaction by means of an amplified signal.
- the nucleic acid probes used in this method are mainly divided into two types: nucleic acid probes for low-risk HPV and nucleic acid probes for high-risk HPV. This method can be used for initial screening of HPV, but it is not possible to determine the specific type of HPV and to determine multiple infections.
- the combination of the above detection methods can improve the sensitivity of HPV detection and reduce the false negative rate of detection.
- the combined cost of these methods is relatively high and generally only applies to HPV testing and cervical cancer screening in economically developed areas. For less economically developed regions, especially in mountainous areas and rural areas, the combined use of these test methods has significant limitations. Therefore, the development of a suitable, low-cost HPV detection method is an urgent problem to be solved.
- the present invention has developed a novel HPV detection method and a kit for use based on Solexa sequencing and PCR index. Party according to the invention The method and kit not only enable high-throughput, low-cost detection of HPV, but also enable accurate typing of HPV. definition
- PCR refers to the polymerase chain reaction.
- Solexa sequencing refers to a new generation of DNA sequencing methods developed in recent years, also known as second generation sequencing.
- Solexa sequencing differs from traditional sequencing methods (eg, Sanger sequencing) in that it performs DNA sequence analysis using the principle of edge-to-edge sequencing.
- Solexa sequencing has the following advantages: 1) low cost, only 1% of the cost of traditional sequencing; 2) high throughput, can simultaneously sequence multiple samples, and one time Solexa sequencing can generate about 50 billion ( 50G) base data; 3) High accuracy (higher than 98.4%), effectively solving the problem of reading polyplexes.
- sequencing depth refers to the number of times a piece of DNA sequence is concentrated in the sequencing data.
- the depth of sequencing can be calculated by dividing the amount of sequencing by the length of the genome, for example, the sequencing depth is 10, indicating that the entire genome has been tested 10 times.
- Solexa sequencing is widely used. It can be used for genome sequencing, genotyping, genetic polymorphism research and more.
- the method of the invention uses Solexa sequencing for the detection of HPV: sequencing of the HPV by the sample to be analyzed, and then using the alignment procedures known in the art, such as BLAST and SOAP, to obtain the resulting sequencing results in the HPV database.
- the reference sequences are aligned to achieve accurate typing of the HPV infected by the sample.
- the HPV database used herein includes those known in the art.
- a sequence of HPV type such as a public database, such as the NCBI database (ht tp: //www.ncb i.nlm.nih.gov/).
- PCR index refers to a small base added to the 5' end of a PCR primer.
- Sequences which can be used to label PCR products by PCR amplification, identify the template source for each PCR product in a mixture of PCR products from different template sources.
- the PCR product can be labeled so that multiple different PCR products can be combined into one library for further analysis and processing.
- Each of the different PCR products in the library has a unique tag, which allows each of the different PCR products to be distinguished from each other and to the PCR template, based on the unique tags in each PCR product.
- PCR products with different labels from each sample can be mixed together to form a library, and then each PCR product in the library can be simultaneously sequenced using high-throughput So l exa sequencing. Finally, in the resulting sequencing data, the unique results can be used to map the sequencing results to individual PCR products (and thus sample templates).
- the label may be introduced only in one primer of the primer pair used for PCR amplification, or may be introduced in both primers of the primer pair.
- each PCR primer pair is combined with a pair of tags into a pair of tag primers, wherein the 5' ends of the forward and reverse PCR primers have a forward tag and a reverse tag, respectively.
- the positive and negative labels and the forward and reverse primer sequences are corresponding, and the forward label and the reverse label may be the same or different.
- PCR amplification primers should be avoided to form secondary structures such as hairpin structures and dimers.
- index pr imer refers to a labeled primer comprising two portions, a label portion and a primer portion, wherein the label portion is used to label PCR in a PCR amplification reaction.
- the product, and the primer portion is complementary to the template base, is used to amplify the template, and wherein the tag portion, optionally through the ligation sequence, is ligated to the 5' end of the primer portion.
- the term "adapter” or "library adap t er” refers to a designed base sequence that can be ligated to an amplified PCR product in a library.
- all amplified PCR products in the library can be sequenced by means of the linker, for example, using sequencing primers designed for the linker (without the use of specific sequencing primers designed for each PCR product).
- the linker of the invention can be ligated to the PCR product by a "PCR-FREE" method.
- PCR-FREE refers to the direct ligation of a linker to a PCR product without performing a PCR reaction, such as by ligation of a linker to a PCR product using DNA ligase.
- the construction of sequencing libraries using the PCR-Free method is known to those skilled in the art, see for example, Na ture Me thods 6, 291-295 (2009).
- the "PCR-FREE” method has no need to perform PCR for the entire process. Advantages: 1) reduced purification steps, reduced time and cost; 2) reduced non-specific amplification; 3) avoidance by PCR during construction of libraries containing many highly similar PCR products Errors, thereby improving the accuracy of the final sequencing results.
- the methods and kits of the invention can utilize at least one linker.
- Different linkers may share the same stretch of sequences (referred to herein as “sequencing sequences") and may further comprise different signature sequences such that different linkers may share the same primer (which is designed for the same sequencing sequence)
- Sequencing is performed and the library of individual PCR products in a mixture of multiple libraries can be discerned using unique signature sequences, ie, further PCR-derived PCR products are further labeled.
- one aspect of the invention provides a set of labels comprising at least 10, preferably at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 Or 95 tags, and the tag has a sequence selected from the group consisting of SEQ ID NOs: 1-95.
- the set of tags comprises at least SEQ ID NO: 1-10, or SEQ ID NO: 11-20, or SEQ ID NO: 21-20, or SEQ ID NO: 31-40, or SEQ ID NO: 41-50, or SEQ ID NO: 51-60, or SEQ ID NO: 61-70, or SEQ ID NO: 71-80, or SEQ ID NO: 81-90, or SEQ ID NO: 91-95
- the label of the invention is used for marking
- the PCR primers shown in SEQ ID NO: 96-106 are used for high throughput HPV sequencing, detection or typing.
- One aspect of the invention provides a tag primer set comprising 11 tag primers, the sequence of the tag primer comprising a tag sequence and a PCR primer sequence, and the tag sequence, optionally linked by a ligation sequence, Said 5' end of the PCR primer sequence, wherein
- the tag sequence is selected from SEQ ID NOs: 1-95, and the tag sequences of each of the 11 tag primers in the tag primer set are the same, and
- the tag primer set of the present invention amplifies at least 16 products of approximately 170 bp corresponding to a highly conserved DNA sequence in the most conserved gene region (L1 region) of the HPV genome. Therefore, the label primer set of the present invention can be used for accurate typing of HPV.
- the set of label primers of the invention can be used for HPV sequencing, detection or typing, such that it can be used for medical purposes, such as diagnosing the presence of HPV and determining the type of HPV, and the like, as well as non-medical uses, such as constructing HPV. Database, identify new types and subtypes of HPV, study the regional characteristics of HPV type distribution, epidemiological studies and vaccine development.
- the set of label primers of the invention can be used to prepare kits that can be used for HPV sequencing, detection or typing.
- Another aspect of the present invention provides a label primer set comprising at least 10, preferably at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, At least 90 or 95 of the label primer sets described above.
- the label sequences used by each label primer set are different from each other.
- the label sequence used in the label primer set comprises at least SEQ ID NO: 1-10, or SEQ ID NO: 11-20, or SEQ ID NO: 21-20, or SEQ ID NO: 31-40, or SEQ ID NO: 41-50, or SEQ ID NO: 51-60, or SEQ ID NO: 61-70, or SEQ ID NO: 71-80, or SEQ ID NO: 81-90, or SEQ ID NO: 91-95, or any of them A combination of two or more, such as the tag sequence set forth in SEQ ID NOs: 1-95.
- the tag primer set of the invention can be used for high throughput HPV sequencing, detection or typing so that it can be used for medical purposes, such as the diagnosis of large scale HPV related diseases and the precise typing of HPV ( Provide basis for clinical diagnosis and treatment options, etc., as well as non-medical uses, such as building HPV databases, identifying new types and subtypes of HPV, studying regional characteristics of HPV type distribution, epidemiological studies, and vaccine development.
- the tag primer set of the invention can be used to prepare a kit that can be used for high throughput HPV sequencing, detection or typing.
- kits comprising the label primer set or label primer set described above.
- the kit of the invention further comprises at least one, preferably at least 2, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100 or at least 200 linkers.
- the linker is suitable for So lexa sequencing, for example it can be used to construct a sequencing library, for example the linker can have a sequence selected from SEQ ID NO: 121-132.
- the sequencing library is constructed using a linker by a PCR-FREE method, such as the DNA ligase method.
- the kit of the invention can be used for high throughput HPV sequencing, detection or typing, and as described above, it can be used for both medical and non-medical uses.
- Another aspect of the invention provides methods for HPV sequencing, detection or typing of one or more samples. The method comprises the steps of amplifying DNA of each sample using a set of label primers or a set of label primers or kits as described above, followed by sequencing to obtain a sequence of the sample.
- Another aspect of the invention provides a method for HPV sequencing, detection or typing of one or more samples comprising the steps of:
- n samples are provided, n being an integer greater than or equal to 1, the sample preferably being from a mammal, more preferably a human, and preferably exfoliated cells; alternatively, the n samples to be analyzed are divided into m groups, m Is an integer and n > m > l ;
- a sample primer set is used to amplify the DNA of the sample
- the tag primer set comprises 11 tag primers, the sequence of the tag primer comprising a tag sequence and a PCR primer sequence, and the tag sequence, optionally linked by a ligation sequence, to the 5' end of the PCR primer sequence, among them
- the tag sequence is selected from the group consisting of SEQ ID NOs: 1-95, and the tag sequences of each of the 11 tag primers are the same, and
- label primer sets used in different samples may be the same or different, and different label primer sets use different label sequences
- step 2) mixing the amplification products obtained by amplification using different label primer sets in step 1) to obtain one or more PCR product libraries;
- step 3 adding one or more sequencing libraries to one or more PCR product libraries obtained in step 2) by a PCR- FREE method, such as DNA ligase method, thereby constructing one or more sequencing libraries, wherein the different sequencing libraries can be used with the linker.
- a PCR- FREE method such as DNA ligase method
- the same or different, and different linkers share the same sequencing sequence, but have different characteristic sequences
- step 5 sequencing one or more sequencing libraries obtained in step 3) or one or more library mixtures obtained in step 4), respectively, using a second generation sequencing technique, preferably a Pair-End technique (eg Solexa, Illumina Hiseq) 2000) sequencing;
- a Pair-End technique eg Solexa, Illumina Hiseq 2000
- the method of the invention uses at least 10, preferably at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or 95 One of the label primer sets described above.
- the tag sequence used comprises at least SEQ ID NO: 1-10, or SEQ ID NO: 11-20, or SEQ ID NO: 21-20, or SEQ ID NO: 31-40, or SEQ ID NO : 41-50 , or SEQ ID NO: 51-60, or SEQ ID NO: 61-70, or SEQ ID NO: 71-80, or SEQ ID NO: 81-90, or SEQ ID NO: 91-95
- the method of the invention uses at least one, preferably at least 2, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100 or At least 200 adaptors, for example, the adaptor can have a sequence selected from the group consisting of SEQ ID NOs: 121-132.
- the obtained sample sequence is compared to the sequence in the HPV database described above to perform accurate HPV typing of the sample.
- the invention provides for the use of So lexa sequencing
- the samples are preferably exfoliated cells, and preferably are derived from an animal, such as a human, the method comprising the steps of:
- Second-generation sequencing technology preferably pair-End technology (such as Solexa, Illumina Hiseq 2000) for sequencing; obtaining sequencing results of all samples;
- DNA extraction is performed using methods well known to those skilled in the art.
- automated DNA extractor and DNA extraction kits can be used for DNA extraction, such as the commercially available KingFier automatic extractor, such as the Thermo Scientific Kingfisher Flex automated magnetic bead extraction and purification system.
- the primer set in 2b) comprises 11 primers, the sequences of which are set forth in SEQ ID NOs: 96-106, respectively.
- the primer set consisting of these 11 primers amplified at least 16 products of approximately 170 bp, which correspond to a highly conserved DNA sequence in the most conserved gene region (L1 region) of the HPV genome. Therefore, accurate sequencing of HPV can be achieved by precisely sequencing the amplified product.
- the number of labels designed in 2b) is at least 10, preferably at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80. At least 90, or at least 100.
- the tag may have a sequence selected from the group consisting of SEQ ID NOs: 1-95.
- the labels used between different sample groups may be the same or different.
- the label introducing the forward primer may be the same as or different from the label introducing the reverse primer.
- the tag designed in 2b) comprises at least SEQ ID NO: 1-10, or SEQ ID NO: 11-20, or SEQ ID NO: 21-20, or SEQ ID NO: 31-40 Or SEQ ID NO: 41-50, or SEQ ID NO: 51-60, or SEQ ID NO: 61-70, or SEQ ID NO: 71-80, or SEQ ID NO: 81-90, or SEQ ID NO : Labels shown in 91-95, or a combination of any two or more of them.
- the label designed in 2b) is as set forth in SEQ ID NOs: 1-95.
- the PCR product library is ligated using a PCR-FREE method, for example using DNA ligase.
- a PCR-FREE method for example using DNA ligase.
- the construction of the sequencing library must be done by the PCR-FREE method.
- a sequencing library is constructed by ligating a linker to a PCR product using conventional pool ing PCR, the resulting library will contain a large number of products that are inconsistent with the original template, resulting in inability to accurately sequence the original template.
- the number of linkers used is at least 1, preferably at least 2, at least 10, at least 20, at least 30, at least 40, at least 50, at least 100 or at least 200
- the linker can have a sequence selected from the group consisting of SEQ ID NOs: 121-132.
- the linker is a commercially available link, such as the PCR-free Index Adapter 01 igo Mix available from Illumina.
- the following PCR-free linkers (underlined portions are characteristic sequences of linkers) can also be used in the present invention.
- PCR-free linker 1 ( SEQ ID NO: 121 ) : ATCACG
- PCR-free linker 2 ( SEQ ID NO: 122 ) : CGATGT
- PCR-free linker 3 ( SEQ ID NO : 123 ) : TTAGGC
- PCR-free linker 4 ( SEQ ID NO: 124 ) : TGACCA
- PCR-free linker 5 ( SEQ ID NO: 125 ) : ACAGTG TTG
- PCR-free linker 6 ( SEQ ID NO: 126 ) : GCCAAT
- PCR-free linker 7 ( SEQ ID NO: 127 ) : CAGATC
- PCR-free linker 8 ( SEQ ID NO: 128 ) : ACTTGA
- PCR-free linker 9 ( SEQ ID NO: 129 ) : GATCAG
- PCR-free linker 10 SEQ ID NO: 130 : TAGCTT
- PCR-free linker 11 SEQ ID NO: 131 : GGCTAC
- PCR-free linker 12 ( SEQ ID NO: 132 ) : CTTGTA
- the method of the invention uses a Solexa sequencer (eg, Illumina Genome Analyzer II x 'sequencer) for Solexa sequencing.
- the HPV database contains Sequences of the HPV type known in the art, such as can be found, for example, in public databases such as the NCBI database (ht tp: //www.ncbi.nlra. nih.gov/).
- the sample may be a shedding cell.
- the sample may be derived from an animal, preferably a mammal, more preferably a human.
- novel HPV detection method of the present invention and the kit for use have the following advantageous aspects with respect to the prior art.
- the present invention uses the So lexa sequencing method for sequencing, and the cost of sequencing is greatly reduced (only 1% of the conventional sequencing method), so that the cost of HPV detection is greatly reduced.
- the use of the method of the present invention also facilitates the discovery of new HPV types, including new subtypes and variants of existing types, to provide more efficient and convenient tools for scientific research.
- Figure 1 is a schematic representation of a PCR product labeled with a tag and a linker with a unique signature sequence.
- a tag is introduced simultaneously across the PCR product of each sample by PCR; a plurality of PCR products with different tags are mixed together for construction of a sequencing library.
- multiple sequencing libraries can be constructed when needed, wherein each sequencing library is labeled by using a linker having a different sequence of features.
- multiple sequencing libraries labeled with linkers with different characteristic sequences can be mixed together and sequenced simultaneously using So l exa sequencing (labels used between different sequencing libraries can be the same or different).
- the sequencing result can be matched to each sample.
- Figure 2 is an agarose gel electrophoresis pattern of a partial PCR product. It can be observed from the electropherogram that the size of the PCR product band is about 17 Obp. Among them, lane M is a 50 bp DNA ladder, and lanes 1-14 are PCR products of randomly selected HPV-positive samples. detailed description
- Example 1 Sample extraction
- DNA was extracted from exfoliated cells of 190 known HC- ⁇ results. Nucleic acid extraction was performed using the program "Bioeasy - 200 ⁇ 1 Blood DNA_F. msz". At the end of the program, an elution product (extracted DNA) of about ⁇ was obtained and used as a template for the next PCR amplification.
- the 190 DNAs obtained in Example 1 were sequentially numbered 1-190 and divided into 2 groups (HPV-1 group: No. 1-95; HPV-2 group: No. 96-190).
- Each label of the design was separately added to the 5' end of the sequence of each primer of the primer set, thereby obtaining 95 label primer sets, wherein each label primer set includes corresponding 6 positive label primers and 5 reversed Label primers, and different label primer sets use different labels (ie, 95 label primer sets correspond to 95 labels).
- Table 2 Sequence information for each primer of the primer set for amplification of HPV DNA without labeling.
- F indicates the forward primer and R indicates the reverse primer.
- the PCR reaction system was 25 ⁇ 1 and its composition was (all reagents were purchased from Enzymatics):
- PCR products remaining in the HPV-1 and HPV-2 groups were each mixed in a 3 ml EP tube (also labeled as HPV-1 and HPV-2) and shaken together.
- 500 ⁇ l of DNA was taken from each of the 2 tube mixtures and purified by column using Qiagen DNA Purification kit according to the manufacturer's instructions to obtain 200 ⁇ l DNA D.
- the DNA concentration of the purified mixture was determined to be 98 ng/ ⁇ (HPV-1 group) and 102 ng/ ⁇ (HPV-2 group) using Nanodrop 8000 (Thermo Fisher Scientific).
- Example 4 Construction of Solexa Sequencing Library
- the DNA end-repairing reaction of the purified two-tube DNA mixture obtained in Example 3 was carried out separately using a Thermomixer (Eppendorf).
- the reaction system for the repair reaction was ⁇ , and its composition was (all reagents were purchased from Enzymatics):
- the reaction element was: 20 ° C, 30 minutes.
- the product of the DNA end-repair reaction was purified and recovered using the QIAquick PCR Pur if icat ion kit according to the manufacturer's instructions. The recovered product was dissolved in 34 ⁇ M El (QIAGEN Elution Buffer).
- the recovered D was subjected to a V-terminal A reaction using a Thermomixer (Eppendorf).
- the reaction system is 50 ul and its composition is (all reagents are purchased from Enzymatics): Reagent volume/reaction
- the reaction conditions were: 37 'C, 30O minutes.
- the reaction system for adding the Solexa linker was 50 ul and its composition was (all reagents were purchased from Illumina):
- the reaction conditions were: 20 ° C, 15 minutes.
- the reaction product was purified using Ampure Beads (Beckman Coulter Genomics) according to the manufacturer's instructions and the product was dissolved in 17 ⁇ l of deionized water.
- the DNA concentration of the product was determined using an Agilent Bioanalyzer 2100 (Agilent) and real-time PCR (QPCR). The results were as follows:
- the sequencing result was matched with each sample.
- the sequencing results for each sample are then compared to the HPV database using alignment procedures known in the art, such as BLAST and S0AP, to achieve HPV detection and accurate typing of HPV.
- the method of the present invention can also accurately classify HPV in a sample.
- the sequencing sequences and type results of the samples corresponding to lanes 1-14 shown in Figure 2 are provided in Table 4.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PL10853857T PL2481818T3 (pl) | 2010-06-30 | 2010-11-15 | Sposób wykrywania wirusa brodawczaka ludzkiego oparty na sekwencjonowaniu metodą Solexa |
AU2010356776A AU2010356776B2 (en) | 2010-06-30 | 2010-11-15 | Method for detecting Human Papilloma Virus based on Solexa sequencing method |
EP10853857.0A EP2481818B1 (en) | 2010-06-30 | 2010-11-15 | Method for detecting human papilloma virus based on solexa sequencing method |
US13/377,116 US9593387B2 (en) | 2010-06-30 | 2010-11-15 | Method for detecting human papilloma virus based on Solexa sequencing method |
SI201030846T SI2481818T1 (sl) | 2010-06-30 | 2010-11-15 | Postopek za detekcijo humanega papiloma virusa na osnovi solexa postopka sekvenciranja |
JP2013516945A JP5923497B2 (ja) | 2010-06-30 | 2010-11-15 | Solexa塩基配列決定法に基づくヒトパピローマウイルス検出方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010213722.7 | 2010-06-30 | ||
CN2010102137227A CN101921874B (zh) | 2010-06-30 | 2010-06-30 | 基于Solexa测序法的检测人类乳头瘤病毒的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012000151A1 true WO2012000151A1 (zh) | 2012-01-05 |
Family
ID=43337089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/001833 WO2012000151A1 (zh) | 2010-06-30 | 2010-11-15 | 基于solexa测序法的检测人类乳头瘤病毒的方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9593387B2 (zh) |
EP (1) | EP2481818B1 (zh) |
JP (1) | JP5923497B2 (zh) |
CN (1) | CN101921874B (zh) |
AU (1) | AU2010356776B2 (zh) |
HK (1) | HK1148789A1 (zh) |
PL (1) | PL2481818T3 (zh) |
SI (1) | SI2481818T1 (zh) |
WO (1) | WO2012000151A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101921748B (zh) * | 2010-06-30 | 2012-11-14 | 上海华大基因科技有限公司 | 用于高通量检测人类乳头瘤病毒的dna分子标签 |
CN102839211A (zh) * | 2011-06-24 | 2012-12-26 | 深圳华大基因科技有限公司 | 用于确定人体具有异常状态的系统和方法 |
WO2012175013A1 (zh) * | 2011-06-24 | 2012-12-27 | 深圳华大基因科技有限公司 | 用于确定人体具有异常状态的系统和方法 |
CN102329876B (zh) * | 2011-10-14 | 2014-04-02 | 深圳华大基因科技有限公司 | 一种测定待检测样本中疾病相关核酸分子的核苷酸序列的方法 |
CN103998625B (zh) * | 2011-11-18 | 2017-06-06 | 华大生物科技(武汉)有限公司 | 用于病毒检测的方法和系统 |
JP6433893B2 (ja) * | 2012-07-03 | 2018-12-05 | インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド | Tm増強ブロッキングオリゴヌクレオチド、ならびに標的濃縮の改善およびオフターゲット選択の低減のためのベイト |
CN102978205B (zh) * | 2012-11-19 | 2014-08-20 | 北京诺禾致源生物信息科技有限公司 | 一种应用于标记开发的高通量测序的接头及其运用方法 |
CN102978206A (zh) * | 2012-11-27 | 2013-03-20 | 北京诺禾致源生物信息科技有限公司 | 一种应用于混合建库的高通量测序接头及其建库方法 |
CN103088120B (zh) * | 2012-11-29 | 2014-10-15 | 北京百迈客生物科技有限公司 | 基于SLAFseq技术的大规模样品基因分型方法 |
CN103898199B (zh) * | 2012-12-27 | 2016-12-28 | 上海天昊生物科技有限公司 | 一种高通量核酸分析方法及其应用 |
WO2015108663A1 (en) * | 2014-01-16 | 2015-07-23 | Illumina, Inc. | Amplicon preparation and sequencing on solid supports |
US20180148780A1 (en) * | 2015-05-22 | 2018-05-31 | University Of Maryland, Baltimore | Next-Generation Sequencing-Based Genotyping Assay for Human Papilloma Virus (HPV) |
KR101651817B1 (ko) | 2015-10-28 | 2016-08-29 | 대한민국 | Ngs 라이브러리 제작용 프라이머 세트 및 이를 이용한 ngs 라이브러리 제작방법 및 키트 |
US20200056224A1 (en) * | 2017-04-18 | 2020-02-20 | Fred Hutchinson Cancer Research Center | Barcoded transposases to increase efficiency of high-accuracy genetic sequencing |
WO2019047109A1 (zh) * | 2017-09-07 | 2019-03-14 | 深圳华大基因股份有限公司 | 一种hpv精确分型的生物信息学分析方法及系统 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050202436A1 (en) * | 2002-07-30 | 2005-09-15 | Baback Gharizadeh | Target-specific multiple sequencing primer pool for microbial typing and sequencing applications in DNA-sequencing technologies |
CN101921748A (zh) * | 2010-06-30 | 2010-12-22 | 深圳华大基因科技有限公司 | 用于高通量检测人类乳头瘤病毒的dna分子标签 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100382703B1 (ko) * | 2000-03-15 | 2003-05-09 | 주식회사 바이오메드랩 | 인유두종바이러스의 유전형 진단키트 및 상기 진단키트의제조방법 |
US20060040286A1 (en) * | 2001-03-28 | 2006-02-23 | Nanosphere, Inc. | Bio-barcode based detection of target analytes |
EP2192199B1 (en) * | 2005-12-08 | 2012-03-14 | Kabushiki Kaisha Toshiba | Method of detecting human papilloma virus by using nucleic acid amplification method and nucleic acid chain-immobilized carrier |
US7910719B2 (en) * | 2005-12-08 | 2011-03-22 | Kabushiki Kaisha Toshiba | Method of detecting human papilloma virus by using nucleic acid amplification method and nucleic acid chain-immobilized carrier |
US20090181389A1 (en) * | 2008-01-11 | 2009-07-16 | Signosis, Inc., A California Corporation | Quantitative measurement of nucleic acid via ligation-based linear amplification |
GB2477439B (en) * | 2008-11-07 | 2012-02-15 | Sequenta Inc | Methods for correlating clonotypes with a disease in a patient |
CN101435002B (zh) | 2008-12-12 | 2012-01-18 | 深圳华大基因科技有限公司 | 一种检测人类乳头瘤病毒基因型的方法 |
CN102367490A (zh) | 2008-12-12 | 2012-03-07 | 深圳华大基因科技有限公司 | 一种检测病毒的方法 |
AU2010232439C1 (en) * | 2009-04-02 | 2017-07-13 | Fluidigm Corporation | Multi-primer amplification method for barcoding of target nucleic acids |
JP5770737B2 (ja) * | 2009-11-06 | 2015-08-26 | ザ チャイニーズ ユニバーシティ オブ ホンコン | サイズに基づくゲノム分析 |
-
2010
- 2010-06-30 CN CN2010102137227A patent/CN101921874B/zh active Active
- 2010-11-15 SI SI201030846T patent/SI2481818T1/sl unknown
- 2010-11-15 US US13/377,116 patent/US9593387B2/en active Active
- 2010-11-15 EP EP10853857.0A patent/EP2481818B1/en active Active
- 2010-11-15 PL PL10853857T patent/PL2481818T3/pl unknown
- 2010-11-15 AU AU2010356776A patent/AU2010356776B2/en active Active
- 2010-11-15 JP JP2013516945A patent/JP5923497B2/ja active Active
- 2010-11-15 WO PCT/CN2010/001833 patent/WO2012000151A1/zh active Application Filing
-
2011
- 2011-03-23 HK HK11102965.4A patent/HK1148789A1/xx unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050202436A1 (en) * | 2002-07-30 | 2005-09-15 | Baback Gharizadeh | Target-specific multiple sequencing primer pool for microbial typing and sequencing applications in DNA-sequencing technologies |
CN101921748A (zh) * | 2010-06-30 | 2010-12-22 | 深圳华大基因科技有限公司 | 用于高通量检测人类乳头瘤病毒的dna分子标签 |
Non-Patent Citations (13)
Title |
---|
"Handbooks of cancer prevention", 2005, IARC PRESS, article "Cervix cancer screening" |
BRINK, A. A.; P. J. SNIJDERS; C. J. MEIJER: "HPV detection methods", DIS. MARKERS, vol. 23, 2007, pages 273 - 281 |
BROWN, C. G. ET AL.: "Solexa/Illumina GAPipeline product and product documentation", 2006, ILLUMINA INC |
COX T; CUZICK J.: "HPV DNA testing in cervical cancer screening: From evidence to policies", GYNEEOL ONCOL, vol. 103, 2006, pages 8 - 11 |
DOORBAR: "J. Molecular biology of human papillomavirus infection and cervical cancer", CLIN. SCI., vol. 110, 2006, pages 525 - 541 |
JONAS BINLADEN ET AL.: "The Use of Coded PCR Primers Enables High-Throughput Sequencing of Multiple Homolog Amplification Products by 454 Parallel Sequencing.", PLOS ONE, no. 2, February 2007 (2007-02-01), pages E197, XP002482385 * |
KULMALA S: "syIjhen. Human papillomavirus testing with the hybrid capture assay and PCR as screening tools", CLIN MICROBIOL, vol. 42, no. 6, 2004, pages 2470 - 2475 |
LOZANO, R.: "Successfully integrating human papillomavirus testing into your practice", ARCH . PATHOL. LAB MED, vol. 127, 2003, pages 991 - 994 |
MATTHIAS MEYER ET AL.: "Targeted high-throughput sequencing of tagged nucleic acid samples.", NUCLEIC ACIDS RESEARCH, vol. 35, no. 15, 2007, pages E97, XP002482386 * |
NATURE METHODS, vol. 6, 2009, pages 291 - 295 |
PECTASIDES D; KANPOSIORAS K; PAPAXOINIS G ET AL.: "Chemotherapy for recurrent cervical cancer", CANCER TREATMENT REVIEWS, vol. 34, no. 7, 2008, pages 603 - 613 |
QUAIL, M. ET AL.: "A large genome center's improvements to the Illumina sequencing system", NAT. METHODS, vol. 5, 2008, pages 1005 - 1010 |
See also references of EP2481818A4 |
Also Published As
Publication number | Publication date |
---|---|
AU2010356776A1 (en) | 2012-03-15 |
EP2481818B1 (en) | 2014-12-31 |
US20130123114A1 (en) | 2013-05-16 |
US9593387B2 (en) | 2017-03-14 |
PL2481818T3 (pl) | 2015-04-30 |
JP2013529471A (ja) | 2013-07-22 |
HK1148789A1 (en) | 2011-09-16 |
CN101921874A (zh) | 2010-12-22 |
SI2481818T1 (sl) | 2015-02-27 |
JP5923497B2 (ja) | 2016-05-24 |
CN101921874B (zh) | 2013-09-11 |
AU2010356776B2 (en) | 2014-10-02 |
EP2481818A4 (en) | 2012-10-31 |
EP2481818A1 (en) | 2012-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2012000151A1 (zh) | 基于solexa测序法的检测人类乳头瘤病毒的方法 | |
WO2012000149A1 (zh) | 用于高通量检测人类乳头瘤病毒的dna分子标签 | |
US20220411780A1 (en) | Detection of circulating tumor dna using double stranded hybrid capture | |
Kroupis et al. | Human papilloma virus (HPV) molecular diagnostics | |
WO2022100444A1 (zh) | 一种用于人乳头瘤病毒hpv分型和整合检测的探针组及其试剂盒 | |
CN114450421A (zh) | 用于人乳头瘤病毒和性传播感染检测、鉴定和定量的方法和组合物 | |
Li et al. | Detection of human papillomavirus genotypes with liquid bead microarray in cervical lesions of northern Chinese patients | |
CN111676218B (zh) | SARS-CoV-2病毒spike基因全长扩增测序方法及其引物 | |
WO2013071520A1 (zh) | 用于病毒检测的方法和系统 | |
CN104928399A (zh) | 引物组、试剂盒及其在hpv全基因组检测中的用途 | |
Souho et al. | Oncogenic human papillomavirus genotyping by multiplex PCR and fragment analysis | |
KR101761701B1 (ko) | Hpv 특이적 프로브 및 이를 포함하는 hpv 유전자형 검사용 dna 칩 | |
KR101401940B1 (ko) | 고위험군 인유두종바이러스 유전자 분석용 키트 및 그 분석방법 | |
PT1694870E (pt) | Iniciadores e sondas para a detecção de genótipos de vph genital | |
US20100285485A1 (en) | Primer, probe, dna chip containing the same and method for detecting human papillomavirus and detection kit thereof | |
Larsson et al. | HPV Genotyping from the high risk mRNA Aptima assay-a direct approach using DNA from Aptima sample tubes | |
JP2013529898A (ja) | 標的遺伝子の多様な変異が存在する遺伝子領域を増幅するためのプライマー組成物 | |
Travasso et al. | Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India | |
RAMESH et al. | Where do we Stand on the Molecular Diagnostics for the Detection of Human Papillomavirus? A Comprehensive Review. | |
CN112921033A (zh) | 核酸组合物和检测试剂盒 | |
Melo et al. | Potential diagnostic techniques for cervical cancer prevention-Review | |
CN109777887B (zh) | 一种检测病毒多种分型的方法和检测试剂盒 | |
KR20110093392A (ko) | Hpv 유전자형 진단용 프로브 및 그 분석방법 | |
Kardani et al. | Diagnosis of HPV Infections, HPV Testing in Patients | |
Leo et al. | High-throughput two-step LNA real time PCR assay for the quantitative detection and genotyping of HPV prognostic-risk groups |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10853857 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010356776 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2010356776 Country of ref document: AU Date of ref document: 20101115 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2013516945 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13377116 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010853857 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3723/CHENP/2012 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |